Phase 2 N=7 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Head and Neck Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm
Phase 2 N=70 The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Serum Kynurenine Levels — 2.39; 1.97; 22.0; 23.3 pmoles/ul — p=<0.05
Phase 2 N=29 Intranasal Insulin in Parkinson's Disease
Parkinson Disease
Primary: Safety Measured by Count of Safety Events — 0; 0; 0; 0 Participants
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
Phase 2 N=78 GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy
Primary: Change From the Baseline in the Total Score of PSP-rating Scale — 4.10; 2.14; 6.46 scores on a scale
Phase 2 N=42 TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Advanced Colorectal Carcinoma · Metastatic Colon Adenocarcinoma · Metastatic Rectal Adenocarcinoma
Primary: Median Progression Free Survival (PFS) — 7.9 months
Phase 2 N=12 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Any Advanced Solid Tumors · Triple Negative Breast Cancer · Non Small Cell Lung Cancer
Primary: Phase 1b: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs), Trial Treatment-related TEAEs and Trial Treatment-related…
Phase 2 N=46 A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Chronic Obstructive Pulmonary Disease
Primary: Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0525; 0.0393; 0.0115; -0.0287 Liters
Phase 2 N=42 Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Parts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events — 3; 3; 3; 3 Participants
Phase 2 N=121 Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Major Pathological Response (MPR) Rate — 45.0; 50.0; 40.0; 55.0 percentage of participants
Phase 2 N=29 A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
Alopecia Areata (AA)
Primary: Evaluation of Adverse Events in Participants — 3; 19; 0; 0 Participants
Phase 2 N=192 Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
Malaria Infection
Primary: Time to Parasitemia Since Negative Blood Smear After Treatment — 62.0; 60.0; NA; NA days
Phase 2 N=201 Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes
Hyperglycemia
Primary: Percentage of Time in Target Glycemic Ranges — 76; 65; 69; 61 percentage of time in target ranges — p=<0.001
Phase 2 N=34 Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors
Survivorship · Cancer · Symptoms and Signs
Primary: Number of Participants Who Logged Data at Least Three Times in the POSTHOC App — 12; 1 Participants